Cargando…

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

BACKGROUND: Enasidenib (IDHIFA(®), AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pharmacodynamics (PK/PD) of orally administered ena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan, Connarn, Jamie N, Chen, Jian, Tong, Zeen, Palmisano, Maria, Zhou, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385784/ https://www.ncbi.nlm.nih.gov/pubmed/30858735 http://dx.doi.org/10.2147/CPAA.S192687

Ejemplares similares

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio
por: Mlugu, Eulambius M., et al.
Publicado: (2022)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time
por: Tung, Norint P., et al.
Publicado: (2022)

No Impact of Vitamin D on the CYP3A Biomarker 4β-Hydroxycholesterol in Patients with Abnormal Glucose Regulation
por: Mannheimer, Buster, et al.
Publicado: (2015)

The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats
por: Ma, Yanrong, et al.
Publicado: (2021)

Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”
por: Kvitne, Kine Eide, et al.
Publicado: (2022)

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio
por: Lee, Jonghwa, et al.
Publicado: (2022)

Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping
por: Suzuki, Yosuke, et al.
Publicado: (2022)

CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women
por: Bergström, Helena, et al.
Publicado: (2021)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome
por: Hukkanen, Janne, et al.
Publicado: (2020)

Serum 4β-hydroxycholesterol increases during fluconazole treatment
por: Lütjohann, Dieter, et al.
Publicado: (2020)

25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes
por: Wang, Yaping, et al.
Publicado: (2021)

Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity
por: Taya, Yuki, et al.
Publicado: (2023)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
por: Hole, Kristine, et al.
Publicado: (2018)

Excitotoxicity increases the release of 24S-hydroxycholesterol via CYP46A1 activation
por: Sodero, Alejandro, et al.
Publicado: (2013)

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model
por: Leil, T A, et al.
Publicado: (2014)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort
por: Le Cornet, Charlotte, et al.
Publicado: (2020)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters
por: Salonurmi, Tuire, et al.
Publicado: (2020)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol
por: Civra, Andrea, et al.
Publicado: (2014)

Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum
por: Bandaru, Veera Venkata Ratnam, et al.
Publicado: (2014)

Inhibition of herpes simplex-1 virus replication by 25-hydroxycholesterol and 27-hydroxycholesterol
por: Cagno, Valeria, et al.
Publicado: (2017)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

Inhibition of Marek’s Disease Virus Replication and Spread by 25-hydroxycholesterol and 27-hydroxycholesterol In Vitro
por: Kamble, Nitin, et al.
Publicado: (2023)

Pregnane X Receptor‒4β‐Hydroxycholesterol Axis in the Regulation of Overweight‐ and Obesity‐Induced Hypertension
por: Rahunen, Roosa, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Evaluation of endogenous and therapeutic 25-hydroxycholesterols in murine models of pulmonary SARS-CoV-2 infection
por: Fessler, Michael B., et al.
Publicado: (2022)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
por: Li, Shuang-long, et al.
Publicado: (2020)

Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range
por: Eide Kvitne, Kine, et al.
Publicado: (2022)

Cellular hormetic response to 27-hydroxycholesterol promotes neuroprotection through AICD induction of MAST4 abundance and kinase activity
por: Gongol, Brendan, et al.
Publicado: (2017)

27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial
por: Sandebring-Matton, Anna, et al.
Publicado: (2021)

Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on β-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells
por: Prasanthi, Jaya RP, et al.
Publicado: (2009)

25-Hydroxycholesterol and 27-hydroxycholesterol inhibit human rotavirus infection by sequestering viral particles into late endosomes
por: Civra, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bcl05n20llji9i5jprt68uig7c